ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY24 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY24 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $4.90-5.05 for the period, compared to the consensus estimate of $4.72. The company issued revenue guidance of $594-602 million, compared to the consensus revenue estimate of $590.33 million. ANI Pharmaceuticals also updated its FY 2024 guidance to 4.900-5.050 EPS.

ANI Pharmaceuticals Stock Up 5.2 %

NASDAQ ANIP opened at $61.44 on Friday. The business has a fifty day moving average price of $58.66 and a two-hundred day moving average price of $61.52. The stock has a market capitalization of $1.29 billion, a PE ratio of 52.51 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81.

Analyst Ratings Changes

Several brokerages recently issued reports on ANIP. Truist Financial lifted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Piper Sandler began coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. Raymond James boosted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.